Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)
Tisdale J, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, Pierciey F, Whitney D, Rogers C, Nnamani M, Foos M, Miller A, Zhang X, Lynch J, Walters M, Kanter J, Bonner M. Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood 2021, 138: 561. DOI: 10.1182/blood-2021-147760.Peer-Reviewed Original ResearchAcute myeloid leukemiaVaso-occlusive eventsCurrent equity holderSevere vaso-occlusive eventsGroup AGroup CMonth 6Clinical outcomesBluebird BioClinical benefitBusulfan conditioningCell doseRisk of AMLAutologous stem cell transplantTricuspid regurgitant jet velocityAdvisory CommitteeDriver mutationsLentiviral vectorsAML driver mutationsOpioid withdrawal syndromeSerious adverse eventsRegurgitant jet velocityFavorable clinical outcomeConsultancy feesStem cell transplantSars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
Lee E, Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, Kruse A, Kessler C, Kruse C, Leavitt A, Lee A, Liebman H, Newland A, Ray A, Tarantino M, Thachil J, Kuter D, Cines D, Bussel J. Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. Blood 2021, 138: 586. PMCID: PMC8701617, DOI: 10.1182/blood-2021-152918.Peer-Reviewed Original ResearchSARS-CoV-2 vaccinesITP exacerbationPre-vaccination baselineBristol-Myers SquibbImmune thrombocytopeniaPlatelet countRescue treatmentDose 2Dose 1Second dosePlatelet decreaseSpeakers bureauSpark TherapeuticsConsultancy feesFirst doseCSL BehringSupport associationsNovo NordiskSARS-CoV-2 vaccinationDiagnosis of ITPAdvisory CommitteeData Safety Monitoring BoardConcurrent autoimmune diseasesMore refractory diseasePrior medical treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply